



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service



Food and Drug Administration  
Rockville MD 20857

DTC

RECEIVED

NOV 05 2002

OFFICE OF PETITIONS

Re: Solage  
Docket No.: 02E-0022

#21

The Honorable James E. Rogan  
Under Secretary of Commerce for Intellectual Property and  
Director of the United States Patent and Trademark Office  
Box Pat. Ext.  
P.O. Box 2327  
Arlington, VA 22202

OCT 31 2002

Dear Director Rogan:

This is in regard to the application for patent term extension for U.S. Patent No. 5,194,247, filed by Bristol-Myers Squibb Company, under 35 U.S.C. section 156 et seq. We have reviewed the dates contained in the application and have determined the regulatory review period for Solage, the human drug product claimed by the patent.

The total length of the regulatory review period for Solage is 2,689 days. Of this time, 1,978 days occurred during the testing phase and 711 days occurred during the approval phase. These periods of time were derived from the following dates:

1. The date an exemption under subsection 505(i) of the Federal Food, Drug, and Cosmetic Act involving this drug product became effective: August 1, 1992.

The applicant claims August 3, 1992, as the date the investigational new drug application (IND) became effective. However, FDA records indicate that the IND effective date was August 1, 1992, which was thirty days after FDA receipt of the IND.

2. The date the application was initially submitted with respect to the human drug product under section 505(b) of the Federal Food, Drug, and Cosmetic Act: December 30, 1997.

FDA has verified the applicant's claim that the new drug application (NDA) for Solage (NDA 20-922) was initially submitted on December 30, 1997.


3. The date the application was approved: December 10, 1999.

FDA has verified the applicant's claim that NDA 20-922 was approved on December 10, 1999.

This determination of the regulatory review period by FDA does not take into account the effective date of the patent, nor does it exclude one-half of the testing phase as required by 35 U.S.C. section 156(c)(2).

Please let me know if we can be of further assistance.

Sincerely yours,



Jane A. Axelrad

Associate Director for Policy  
Center for Drug Evaluation and Research

cc: Charles J. Zeller  
Bristol-Myers Squibb Company  
2 Blachley Road  
Stamford, CT 06922